Drug intelligence / Profile preview

TBT401

Development stage: Preclinical
Lead developer: FibroGenesis
Modality: Cell Therapies

Overview

TBT401 is a preclinical cell therapy candidate developed by FibroGenesis (formerly SpinalCyte). It utilizes human dermal fibroblasts (HDFs) in conjunction with 3D bioprinting technology to create constructs intended for tissue generation and regeneration. The platform leverages the regenerative potential of fibroblasts, which are known to secrete various growth factors and extracellular matrix components. By using 3D bioprinting, the therapy aims to provide structural support and a biological environment conducive to repairing or replacing damaged tissues.

Beyond the preview

Go deeper on TBT401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBT401.

Explore the full profile